Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]

Investment Rating - The report does not explicitly state an investment rating for the skin disease drug industry Core Insights - The skin disease drug industry focuses on treating various skin conditions, with a strong market demand driven by increasing patient needs and innovative treatment methods [5][6] - The market size for skin disease drugs is projected to grow from 2.076 billion RMB in 2019 to 2.575 billion RMB in 2023, with a compound annual growth rate (CAGR) of 5.54%. It is expected to reach 3.551 billion RMB by 2028, with a CAGR of 6.32% [9][10] - The industry has evolved from the use of natural substances to synthetic drugs and innovative biopharmaceuticals, with significant advancements in drug formulations and delivery systems [8] Market Background - The skin disease drug industry is characterized by high regulatory barriers and significant policy impacts, but the growing patient demand is driving market expansion [5] - The prevalence of skin diseases in China is high, with estimates indicating that 40%-70% of the population is affected, leading to a strong treatment willingness and a growing market for topical medications [13] Market Status - The market supply is constrained by the complexity of developing topical formulations, with only five new topical drugs approved in the last five years compared to 80 oral formulations [11] - The demand for skin disease treatments is increasing due to rising incidence rates and the convenience of topical medications, which patients can self-administer [13] Market Competition - The competitive landscape features a tiered structure, with leading companies like Huabang Pharmaceutical and ZhiYuan Pharmaceutical dominating the market [18][19] - The online sales channel for skin disease drugs has grown significantly, with its share increasing from 9.0% in 2019 to 22.9% in 2023, reflecting a CAGR of 24.3% [18] Development Trends - Technological innovations, particularly in biopharmaceuticals and AI-driven drug development, are expected to be key growth drivers in the industry [32] - Local companies are likely to strengthen their market positions through channel advantages and innovation, while foreign companies may deepen their local presence through partnerships [33] - Policy changes and capital investments are anticipated to accelerate industry upgrades, enhancing the accessibility of innovative drugs [34]

股票代码：000999 股票简称：华润三九 编号：2025—053 特此公告。 华润三九医药股份有限公司 华润三九医药股份有限公司 关于高级管理人员离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"本公司"）董事会于 2025 年 6 月 24 日收到副总裁黄先锋先生提交的辞职报告。黄先锋先生由于工作调整原因，提请 辞去公司副总裁职务，辞职后黄先锋先生继续在公司担任党委专职副书记职务。 黄先锋先生担任副总裁职务的原定任期至公司第九届董事会届满之日止，根据《公 司章程》及有关规定，黄先锋先生辞去公司副总裁职务的申请自辞职报告送达公司董事 会时生效，本次辞职不会影响公司日常经营管理。 截至本公告日，黄先锋先生未持有本公司股票，不存在应履行而未履行的承诺事项。 公司董事会谨对黄先锋先生在担任公司副总裁期间对公司做出的贡献表示衷心感 谢！ 董事会 二○二五年六月二十四日 1 ...

股票代码：000999 股票简称：华润三九 编号：2025—052 华润三九医药股份有限公司 关于控股子公司昆药集团担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 一、 担保情况概述 1. 担保事项履行的相关程序 为适应昆药集团及其相关下属公司业务发展需要，满足相关公司融资担保需求，经华润 三九董事会 2025 年第五次会议及 2024 年年度股东会审议通过，2025 年度昆药集团及其下 属子公司预计为昆药集团下属子公司不超过人民币 4.5615 亿元的银行融资授信业务提供连 被担保人：曲靖市康桥医药有限责任公司（以下简称"曲靖康桥"）、昆药商业（昭通） 医药有限公司（以下简称"昭通医药"）。上述被担保人均为华润三九医药股份有限公 司（以下简称"华润三九"）控股子公司昆药集团股份有限公司（以下简称"昆药集团"） 全资子公司昆药集团医药商业有限公司（以下简称"昆药商业"）的控股子公司，不存 在关联担保。 本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为 1,250 万元，累计已实际为其提供的担保余额为 ...

Group 1: Company Strategy and Development - The company plans to continue its dual-driven approach of internal and external growth through mergers and acquisitions, focusing on strategic emerging industries and brand assets [2][4] - The company aims to exceed its "14th Five-Year Plan" revenue doubling target, with expectations for an aggressive "15th Five-Year Plan" that emphasizes competitiveness and innovation [6] - The collaboration between Huaren Sanjiu, Tianshili, and Kunyu Group is expected to enhance their market positions, with a clear vision for future development [4] Group 2: Product Development and Market Response - The company is closely monitoring respiratory disease incidence rates, maintaining its market outlook for respiratory products, and expanding its product range [5] - New products like 999 Yiqi Qingfei Granules have been approved to address recovery symptoms from severe respiratory illnesses, filling a market gap [5] - The company is adapting to retail market pressures while maintaining a long-term growth outlook, emphasizing the importance of digital transformation and consumer trust in product quality [10] Group 3: Financial Performance and Shareholder Engagement - The company has consistently increased its cash dividend payout ratio, currently stabilizing between 40%-50% [8] - Future stock incentive plans are being considered as part of state-owned enterprise reforms, aiming to enhance shareholder satisfaction [7] - The company has performed well in state-owned enterprise reform evaluations, indicating strong market management [7] Group 4: Sales and Marketing Strategy - The sales expense ratio is expected to stabilize as the company’s CHC and prescription drug businesses align their sales models [11] - The company anticipates a gradual decrease in sales expense ratios due to the implementation of centralized procurement policies [11]

上海市锦天城（深圳）律师事务所 关于 华润三九医药股份有限公司 第三个解除限售期解除限售条件未成就暨回购注销部分限 制性股票相关事宜的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21、22、23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所法律意见书 二、 第三个解除限售期解除限售条件未成就暨回购注销部分限制性股票的批准与授权 .... 11 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于华润三九医药股份有限公司 成就暨回购注销部分限制性股票相关事宜的 法律意见书 致：华润三九医药股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受华润三九医药 股份有限公司（以下简称"公司"或"华润三九"）的委托，就公司 2021 年限 制性股票激励计划（以下简称"激励计划"或"本次激励计划"）相关事宜提供 专项法律服务。 本所根据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共 和国证券法》 （以下简称"《证券法》"）、 《深圳证券交易所股票上市规则（2025 年 修订）》 ...

股票代码：000999 股票简称：华润三九 编号：2025—050 华润三九医药股份有限公司 关于 2021 年限制性股票激励计划第三个解锁期解锁条件未成就 暨回购注销首次授予、预留授予部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： ●本次回购注销的限制性股票数量：474.7942 万股，其中首次授予的限制性股票数量 为 408.7113 万股，预留授予的限制性股票数量为 66.0829 万股（具体股数以中国证券登记 结算有限责任公司深圳分公司提供的为准），涉及人数 363 人。 ●本次回购限制性股票的价格：408.7113 万股（具体股数以中国证券登记结算有限责 任公司深圳分公司提供的为准）首次授予限制性股票以调整后回购价格（5.7817625 元/股） 进行回购注销；66.0829 万股（具体股数以中国证券登记结算有限责任公司深圳分公司提供 的为准）预留授予限制性股票以调整后回购价格（11.3988165 元/股）进行回购注销；回购 资金均为公司自有资金。 ●本次回购注销部分限制性股票尚需提交公司股东会进行审议。 华润 ...

股票代码：000999 股票简称：华润三九 编号：2025—048 华润三九医药股份有限公司 二、 关于2021年限制性股票激励计划第三个解锁期解锁条件未成就回购注销首次授予、 预留授予部分限制性股票的议案 本议案提交董事会前已经公司董事会薪酬与考核委员会审议通过。 详细内容请参见《华润三九医药股份有限公司关于 2021 年限制性股票激励计划第三个 解锁期解锁条件未成就暨回购注销首次授予、预留授予部分限制性股票的公告》（2025-050）。 董事长邱华伟先生、董事周辉女士为 2021 年限制性股票激励计划的激励对象，回避了 对本议案的表决。 2025 年第九次董事会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司董事会 2025 年第九次会议于 2025 年 6 月 16 日下午在华润 三九医药工业园综合办公中心 107 会议室以现场会议方式召开。会议通知以书面方式于 2025 年 6 月 13 日发出。会议由董事长邱华伟先生主持，本次会议应到董事 11 人，实到董事 11 人。公司监事会成员和部分高级管理人员列席会议。本 ...

华润三九医药股份有限公司 关于召开 2025 年第四次临时股东会通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"）董事会 2025 年第九次会议审议通过了 《关于召开 2025 年第四次临时股东会的议案》 ，公司定于 2025 年 7 月 7 日（星期一）召开 股票代码：000999 股票简称：华润三九 编号：2025—051 一、召开会议的基本情况 程》的规定。本次股东会由公司第九届董事会 2025 年第九次会议决定召开。 现场会议：2025 年 7 月 7 日下午 14:30 网络投票时间：2025 年 7 月 7 日。其中，通过深圳证券交易所交易系统投票的时间为 互联网投票系统投票的时间为 2025 年 7 月 7 日 9：15 至 15:00 期间的任意时间。 通过深圳证券交易所交易系统和互联网投票系统（http://wltp.cninfo.com.cn）向全体股 东提供网络形式的投票平台，股东可以在网络投票时间内通过上述系统行使表决权。 公司股东只能选择现场投票（可以委托代理人代为投票）或者网络投票中的 ...

Core Viewpoint - The company held its sixth supervisory board meeting in 2025, where it approved resolutions regarding the unfulfilled conditions of the third unlocking period of the 2021 restricted stock incentive plan [1][2] Group 1 - The meeting was conducted on June 16, 2025, at the company's industrial park and was attended by all five supervisors, confirming its legality and effectiveness [1] - The first resolution addressed the unfulfilled conditions of the third unlocking period of the 2021 restricted stock incentive plan, leading to the decision to repurchase and cancel the initially granted and reserved restricted stocks [1][2] - The second resolution, which also received unanimous approval, will be submitted to the shareholders' meeting for further deliberation [2]